¼¼°èÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå º¸°í¼ : Ä¡·á À¯Çü, ¾Ë·¹¸£±â À¯Çü, À¯Åë ä³Î, Áö¿ªº°(2025-2033³â)
Allergy Immunotherapies Market Report by Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy ), Allergy Type, Distribution Channel, and Region 2025-2033
¼¼°èÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2024³â 34¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 75¾ï ´Þ·¯¿¡ À̸£¸ç 2025³âºÎÅÍ 2033³â±îÁö 8.29%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ½ÃÀåÀº ¾Ë·¹¸£±â ÁúȯÀÇ À¯º´·ü »ó½Â, ¾Ë·¹¸£±âÀÇ È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î¼ÀÇ ¸é¿ª¿ä¹ý¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¸é¿ª¿ä¹ý Ä¡·á¡¤±â¼úÀÇ ÇöÀúÇÑ °³¹ß, ¾Ë·¹¸£±â ¿¬±¸¿¡ ´ëÇÑ À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥°ú ÀÚ±Ý Áö¿ø, ¸ÂÃãÇü ÀÇ·á ¹× ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.
¾Ë·¹¸£±â¼º ¸é¿ª¿ä¹ýÀº °¨ÀÛÀÛ¿ë ¶Ç´Â Àú°¨ÀÛ¿ä¹ýÀ¸·Îµµ ºÒ¸®¸ç, ´Ù¾çÇÑ À½½Ä, ¾à¹°, ¹úµ¶, ½Ò°ú ²É°¡·ç, ¿©µå¸§ µîÀÇ ¾Ë·¹¸£°Õ¿¡ ´ëÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ¿¹¹æÀû Ä¡·á¹ýÀÔ´Ï´Ù. ¾Ë·¹¸£°ÕÀÇ ¾çÀ» ¼¼È÷ Áõ°¡½ÃÅ´À¸·Î½á ¸é¿ª°èÀÇ ¹ÝÀÀÀ» º¯È½Ãŵ´Ï´Ù. Ä¡·á¸¦ ½ÃÀÛÇϱâ Àü¿¡ ¾Ë·¹¸£±â Àü¹®ÀÇ¿Í È¯ÀÚ´Â ¾Ë·¹¸£±â Áõ»óÀÇ À¯¹ß ÀÎÀÚ¸¦ ºÐ¼®ÇÏ°í ¾Ë·¹¸£°ÕÀ» È®ÀÎÇϱâ À§ÇØ ÇǺΠ°Ë»ç¿Í Ç÷¾× °Ë»ç¸¦ ½Ç½Ã ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¼º ¸é¿ª¿ä¹ýÀº ¿°ÁõÀ» ¾ïÁ¦Çϰí, Àå±âÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í, ¸é¿ª°ü¿ëÀ» Áõ°¡½Ã۰í, Áúº´ÀÇ °æ°ú¸¦ ¹Ù²Ù°í, ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
ÃÖ±Ù ¸é¿ª°èÀÇ ÀÛ¿ë¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ È¯°æ ¿äÀΰú »ýȰ ½À°üÀ¸·Î ÀÎÇØ ¼¼°è ¾Ë·¹¸£±â À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÏ°í ¼Òµæ ¼öÁØÀÌ Áõ°¡ÇÏ°í °Ç° °ü¸® ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °íµµÀÇ Àå±â Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¼¼°èÀÇ Á¤ºÎ±â°ü°ú ºñÁ¤ºÎ Á¶Á÷ÀÇ ¿©·¯ ³ë·ÂÀ¸·Î ÀÓ»ó ¿¬±¸°³¹ß ¿¹»êÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃֽŠÀǾàǰ °³¹ß ±â¼úÀ» ÅëÇØ Á¦¾à ȸ»ç´Â ´Ù¾çÇÑ ¾Ë·¹¸£±â¸¦ Ä¡·áÇÏ´Â È¿À²ÀûÀÎ ¸é¿ª ¿ä¹ýÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. À̰ÍÀº ¾Ë·¹¸£±â Áø´Ü ºÐ¾ßÀÇ Áøº¸¿Í ÇÔ²² ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- 2024³â ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â?
- 2025-2033³â ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ¼¼°è ½ÃÀå ¼ºÀå·üÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀå¿¡ COVID-19ÀÇ ¿µÇâÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀåÀÇ Ä¡·á À¯Çüº° ³»¿ªÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀåÀÇ ¾Ë·¹¸£±â À¯Çü ´Ù¸¥ °íÀåÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀå ÆÇ¸Å Ã¤³Î ´Ù¸¥ °íÀåÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
- ¼¼°è ¾Ë·¹¸£±â ¸é¿ª ¿ä¹ý ½ÃÀå¿¡¼ ÁÖ¿ä ±â¾÷/±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»çÀÇ ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°
- ½ÃÀå ºÐ¼® : ¾Ë·¹¸£±â À¯Çüº°
- ½ÃÀå ºÐ¼® : À¯Åëä³Îº°
- ½ÃÀå ºÐ¼® : Áö¿ªº°
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª: Ä¡·á À¯Çüº°
- ÇÇÇϸ鿪¿ä¹ý(SCIT)
- ¼³ÇÏ ¸é¿ª¿ä¹ý(SLIT)
Á¦7Àå ½ÃÀå ºÐ¼® : ¾Ë·¹¸£±â À¯Çüº°
- ¾Ë·¹¸£±â¼º ºñ¿°
- õ½Ä
- À½½Ä ¾Ë·¹¸£±â
- µ¶ ¾Ë·¹¸£±â
- ±âŸ
Á¦8Àå ½ÃÀå ºÐ¼® : À¯Åëä³Îº°
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°
- À¯·´
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä«
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ Çù»ó·Â
- °ø±Þ±â¾÷ÀÇ Çù»ó·Â
- °æÀïµµ
- ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
- °¡°Ý ÁöÇ¥
- °¡°Ý±¸Á¶
- ¸¶Áø ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- ALK-Abello A/S
- Allergy Therapeutics
- Stallergenes Greer
- HAL Allergy Holding BV
- DBV Technologies
- Merck KGaA
- Aimmune Therapeutics
- Circassia Pharmaceuticals
- Anergis SA
- Biomay AG
JHS
The global allergy immunotherapies market size reached USD 3.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.5 Billion by 2033, exhibiting a growth rate (CAGR) of 8.29% during 2025-2033. The market is propelled by the rising prevalence of allergic conditions, increasing awareness about immunotherapy as an effective treatment for allergies, significant developments in immunotherapy treatments and technologies, favorable government policies and funding for allergy research, and customized medicine and tailored treatment approaches.
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system's response by gradually increasing the doses of the allergen. Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient's life.
In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world. Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.
Key Market Segmentation:
Breakup by Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
Breakup by Allergy Type:
- Allergic Rhinitis
- Asthma
- Food Allergy
- Venom Allergy
- Others
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Breakup by Region:
- Europe
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, etc.
Key Questions Answered in This Report
- 1.What was the size of the global allergy immunotherapies market in 2024?
- 2.What is the expected growth rate of the global allergy immunotherapies market during 2025-2033?
- 3.What are the key factors driving the global allergy immunotherapies market?
- 4.What has been the impact of COVID-19 on the global allergy immunotherapies market?
- 5.What is the breakup of the global allergy immunotherapies market based on the treatment type?
- 6.What is the breakup of the global allergy immunotherapies market based on the allergy type?
- 7.What is the breakup of the global allergy immunotherapies market based on the distribution channel?
- 8.What are the key regions in the global allergy immunotherapies market?
- 9.Who are the key players/companies in the global allergy immunotherapies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Allergy Immunotherapies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Treatment Type
- 5.5 Market Breakup by Allergy Type
- 5.6 Market Breakup by Distribution Channel
- 5.7 Market Breakup by Region
- 5.8 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Subcutaneous Immunotherapy (SCIT)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Sublingual Immunotherapy (SLIT)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Allergy Type
- 7.1 Allergic Rhinitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Asthma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Food Allergy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Venom Allergy
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 Europe
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 North America
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Asia Pacific
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Middle East and Africa
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Latin America
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
- 13.1 Price Indicators
- 13.2 Price Structure
- 13.3 Margin Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 ALK-Abello A/S
- 14.3.2 Allergy Therapeutics
- 14.3.3 Stallergenes Greer
- 14.3.4 HAL Allergy Holding B.V.
- 14.3.5 DBV Technologies
- 14.3.6 Merck KGaA
- 14.3.7 Aimmune Therapeutics
- 14.3.8 Circassia Pharmaceuticals
- 14.3.9 Anergis SA
- 14.3.10 Biomay AG